---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-008516"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:25:07.868559+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo announces termination of Novartis and Biogen collaborations; loses milestone/royalty potential

## Summary
- Novartis terminated collaboration (effective June 11, 2023); Sangamo loses up to $720M in milestones and royalties.
- Biogen terminated collaboration (effective June 15, 2023); Sangamo loses up to $2.37B in milestones and royalties.
- Sangamo will explore internal development or new partners for CNS programs but faces uncertainty.
- Company expects existing cash runway of at least 12 months from Dec. 31, 2022 remains adequate despite terminations.

## SEC filing metadata
- accession: 0001628280-23-008516
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023008516/0001628280-23-008516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023008516/sgmo-20230313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-008516
- JSON: https://secwatch.observer/filing/0001628280-23-008516.json
- Plain text: https://secwatch.observer/filing/0001628280-23-008516.txt

## Key facts
- Material Agreements
  SANGAMO THERAPEUTICS, INC terminated Collaboration and License Agreement with Novartis Institutes for BioMedical Research, Inc. (effective 2023-06-11).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Novartis Institutes for BioMedical Research, Inc.
  - Effective: 2023-06-11
  source text: On March 13, 2023, Novartis Institutes for BioMedical Research, Inc. ("Novartis") notified Sangamo Therapeutics, Inc. ("Sangamo") of its termination for convenience, effective June 11, 2023 (the "Novartis Termination Date"), of the Collaboration and License Agreement (the "Novartis Agreement") by and between Novartis and Sangamo dated July 27, 2020
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828023008516/0001628280-23-008516-index.htm
- Material Agreements
  SANGAMO THERAPEUTICS, INC terminated Collaboration and License Agreement with Biogen MA, Inc. (effective 2023-06-15).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Biogen MA, Inc.
  - Effective: 2023-06-15
  source text: On March 17, 2023, Biogen MA, Inc. and its affiliate, Biogen International GmbH (together, "Biogen") notified Sangamo of its termination for convenience, effective June 15, 2023 (the "Biogen Termination Date"), of the Collaboration and License Agreement (the "Biogen Agreement") by and between Biogen and Sangamo dated February 26, 2020
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828023008516/0001628280-23-008516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.